Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 1, Pages 177-186Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.30049
Keywords
irinotecan; KRAS wild-type; MET inhibitor; metastatic colorectal cancer; tivantinib
Categories
Funding
- Pfizer
- Sarah Cannon Research Institute
- Daiichi Sankyo, Inc.
- F. Hoffmann-La Roche Ltd
- Amgen
- Alchemia
- Lexicon
- Incyte
- Pharmacyclics
- Genentech
- Sanofi Aventis
- Daiichi Sankyo, Inc., of the Daiichi Sankyo Group
- ArQule, Inc.
Ask authors/readers for more resources
Cetuximab in combination with an irinotecan-containing regimen is a standard treatment in patients with KRAS wild-type (KRASWT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab+irinotecan (CETIRI) based on preclinical evidence that activation of the MET pathway may confer resistance to anti-EGFR therapy. Previously treated patients with KRASWT advanced or mCRC were enrolled. The phase 1, open-label 3+3, dose-escalation study evaluated the safety and maximally tolerated dose of tivantinib plus CETIRI. The phase 2, randomized, double-blinded, placebo-controlled study of biweekly CETIRI plus tivantinib or placebo was restricted to patients who had received only one prior line of chemotherapy. The phase 2 primary endpoint was progression-free survival (PFS). The recommended phase 2 dose was tivantinib (360 mg/m(2) twice daily) with biweekly cetuximab (500 mg/m(2)) and irinotecan (180 mg/m(2)). Among 117 patients evaluable for phase 2 analysis, no statistically significant PFS difference was observed: 8.3 months on tivantinib vs. 7.3 months on placebo (HR, 0.85; 95% confidence interval, 0.55-1.33; P=0.38). Subgroup analyses trended in favor of tivantinib in patients with MET-High tumors by immunohistochemistry, PTEN-Low tumors, or those pretreated with oxaliplatin, but subgroups were too small to draw conclusions. Neutropenia, diarrhea, nausea and rash were the most frequent severe adverse events in tivantinib-treated patients. The combination of tivantinib and CETIRI was well tolerated but did not significantly improve PFS in previously treated KRASWT mCRC. Tivantinib may be more active in specific subgroups. What's new? Is there a way to head off drug-resistant colorectal cancer? A new study investigates whether a new drug, tivantinib, can improve survival by staving off tumor cells' resistance to chemotherapy. Previous results have shown that the MET signaling pathway contributes to the spread of cancer and the onset of resistance. The authors added the MET inhibitor tivantinib to the regimen of cetuximab and irinotecan. The tivantinib did not improve survival times, but the drug might yet prove effective among specific tumor subgroups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available